UNLABELLED: THE NEED FOR PREVENTION: Women throughout the world face a growing risk of infection with HIV. Consistent condom use, one cornerstone of primary prevention strategy, is not always feasible for many women. Consequently, women urgently need infection prevention technology that is within their personal control. METHODS: This session will review current efforts to develop and test female-controlled methods for preventing sexual transmission of HIV and other sexually transmitted pathogens. Both physical and chemical methods will be summarized, including recent findings concerning the efficacy and acceptability of the vaginal pouch (female condom), as well as an overview of research on vaginal microbicides. Data from studies of existing over-the-counter spermicides will be reviewed. The wide range of novel microbicidal products currently being evaluated in the laboratory and early clinical trials demonstrate the breadth of possibilities presented by chemical barrier methods. However, formidible challenges face public and private sector research and development efforts. This session will conclude by highlighting several issues related to the clinical evaluation and introduction of female-controlled prevention technology.
UNLABELLED: THE NEED FOR PREVENTION: Women throughout the world face a growing risk of infection with HIV. Consistent condom use, one cornerstone of primary prevention strategy, is not always feasible for many women. Consequently, women urgently need infection prevention technology that is within their personal control. METHODS: This session will review current efforts to develop and test female-controlled methods for preventing sexual transmission of HIV and other sexually transmitted pathogens. Both physical and chemical methods will be summarized, including recent findings concerning the efficacy and acceptability of the vaginal pouch (female condom), as well as an overview of research on vaginal microbicides. Data from studies of existing over-the-counter spermicides will be reviewed. The wide range of novel microbicidal products currently being evaluated in the laboratory and early clinical trials demonstrate the breadth of possibilities presented by chemical barrier methods. However, formidible challenges face public and private sector research and development efforts. This session will conclude by highlighting several issues related to the clinical evaluation and introduction of female-controlled prevention technology.
Entities:
Keywords:
Americas; Barrier Methods; Clinical Research; Clinical Trials; Contraception; Contraceptive Agents; Contraceptive Methods; Developed Countries; Diseases; Economic Factors; Family Planning; Hiv Infections--prevention and control; Infections; Literature Review; North America; Northern America; Reproductive Tract Infections; Research And Development; Research Methodology; Sexually Transmitted Diseases--prevention and control; Spermicidal Contraceptive Agents; Technology; United States; Viral Diseases
Authors: Nancy Van Devanter; Virginia Gonzales; Cheryl Merzel; Nina S Parikh; David Celantano; Judith Greenberg Journal: Am J Public Health Date: 2002-01 Impact factor: 9.308
Authors: Youssef Gali; Olivier Delezay; Joachim Brouwers; Noura Addad; Patrick Augustijns; Thomas Bourlet; Hind Hamzeh-Cognasse; Kevin K Ariën; Bruno Pozzetto; Guido Vanham Journal: Antimicrob Agents Chemother Date: 2010-10-04 Impact factor: 5.191
Authors: Lin Wang; Alexandra Beumer Sassi; Dorothy Patton; Charles Isaacs; B J Moncla; Phalguni Gupta; Lisa Cencia Rohan Journal: Drug Dev Ind Pharm Date: 2011-12-10 Impact factor: 3.225
Authors: Sharon A Abbott; Barbara A Friedland; Avina Sarna; Lauren L Katzen; Ulrike Rawiel; Aylur K Srikrishnan; C S Shalini; Waimar Tun; Christine A Kelly; Suniti Solomon; Barbara S Mensch Journal: AIDS Behav Date: 2013-07
Authors: Joseph L Fava; Jacob J van den Berg; Rochelle K Rosen; Liz Salomon; Sara Vargas; Anna L Christensen; Megan Pinkston; Kathleen M Morrow Journal: Sex Health Date: 2013-08 Impact factor: 2.706